Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer

Abu-Hamar, Abd El Halim; Mansour, Sahar; Shebiney, Mohamed El; Bary, Naser Mohamed Abd El; Sadaka, Emad; Maria, Alaa

doi:10.1016/s1658-3876(10)50022-0

Cited by 3 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the adverse events observed were hematological toxicity, among which neutropenia was the most common adverse effect. The incidence of grade 3/4 neutropenia of the D3P arm of the present study was similar to that reported by Naito et al (93%) [ 8 ] and Abu-Hamar et al(85.7%), [ 10 ] while much higher than TAX-327 (32%). [ 6 ] Febrile neutropenia (5.41%) of the D3P arm in this study was close to TAX-327 (3%), nevertheless lower than the results of Naito et al(16.3%) [ 8 ] and Abu-Hamar et al(14.3%).…”

Section: Discussionsupporting

confidence: 91%

“…Contradictory to the present study and previous results, the study conducted by Abu-Hamar [ 10 ] showed that median OS was 15 months for mCRPC patients with D3P arm, and they speculated that the docetaxel-based therapy presented a poor survival outcome for Egyptian. Meanwhile, Thatai et al [ 21 ] reported that the time to PSA progression was significantly longer for whites than for blacks, while no statistically significant difference by race was found in OS and PSA response rate.…”

Section: Discussionsupporting

confidence: 68%

“…[ 6 ] Febrile neutropenia (5.41%) of the D3P arm in this study was close to TAX-327 (3%), nevertheless lower than the results of Naito et al(16.3%) [ 8 ] and Abu-Hamar et al(14.3%). [ 10 ] It was likely that population ethnicity might have an impact on both appropriate treatment dosage and response. For instance, Naito et al [ 8 ] adopted a 70 mg/m 2 dose for D3P arm, which was considered more appropriate for Japanese patients based on their studies of maximum tolerated dose of docetaxel.…”

Section: Discussionmentioning

confidence: 99%

“…Whether docetaxel-based chemotherapy will benefit the Asian population is still controversial, because of the lack of strong support from clinical trials. [ 10 – 13 ] The clinical data of TAX-327 and SWOG-9916 were collected from major clinical centers around the world but without Asia centers. [ 6 , 7 ] What’s more, no phase III clinic trial of docetaxel-based chemotherapy has been conducted among Chinese population.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer

Zhou

Zeng

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

PurposeTo explore the feasibility and efficacy of docetaxel plus prednisone for Chinese population with metastatic castration refractory prostate cancer (mCRPC).Patients and methodsA total of 228 patients recruited from 15 centers were randomized to receive 10 cycles of D3P arm (docetaxel: 75 mg/m2, intravenous infusion, every three weeks; Prednisone 10mg orally given daily) or M3P arm (mitoxantrone: 12 mg/m2, intravenous infusion, every three weeks; Prednisone 10mg orally given daily). Primary end point was overall survival, and secondary end points were events progression-free survival (PFS), response rate, response duration. Quality of life (QoL) was also assessed in both treatment groups.ResultsThe median overall survival was 21.88 months in D3P arm and 13.67 months in M3P arm (P = 0.0011, hazard ratio = 0.63, 95% confidence interval, 0.46–0.86). Subgroup analysis was consistent with the results of overall analysis. Events progression-free survival (pain, PSA, tumor and disease) were significantly improved in D3P arm compared with M3P arm. PSA response rate was 35.11% for patients treated by D3P arm and 19.39% for M3P arm (P = 0.0155). Pain response rate was higher in D3P arm (61.11%, P = 0.0011) than in M3P (23.08%) arm. No statistical differences were found between D3P arm and M3P arm for QoL, tumor response rate and response duration of PSA and pain. The tolerability and overall safety of D3P arm were generally comparable to that of M3P arm.ConclusionsCompared with M3P arm, D3P arm significantly prolonged overall survival for the Chinese patients with mCRPC and improved the response rate for PSA and pain.Trial Registration clinicaltrials.gov NCT00436839

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer

Zhou

Zeng

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

show abstract

A Systematic Review of the Treatment Outcomes among Prostate Cancer Patients in Africa

Degu

Mekonnen²,

Njogu

2022

Cancer Investigation

View full text Add to dashboard Cite

A multicenter observational study of the real‐world use of docetaxel for metastatic castration‐resistant prostate cancer in China

Sun

Guo

et al. 2019

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

AimTo investigate the use of docetaxel for the treatment of metastatic castration‐resistant prostate cancer (mCRPC) in real‐world clinical practice in China.MethodsThis single‐arm, prospective, observational study was conducted at 32 study centers in China and included male patients aged ≥18 years with histologically confirmed prostate cancer who received ≥1 dose of docetaxel following failure of hormonal therapy (disease progression with serum testosterone <50 ng/dL). The primary aim was to investigate patterns of docetaxel treatment.ResultsOverall 403 patients were included between August 2011 and June 2016; patients initiated docetaxel after failure of first‐ (42.2% [170]), second‐ (31.0% [125]) and ≥third‐line (12.7% [51]) hormonal therapy, estramustine (11.4% [46]) or other (2.7% [11]). The planned cycles of docetaxel therapy were completed by 30.8% of patients, and the mean (SD) number of cycles received was 4.4 (2.86). Median overall survival (mOS) was 22.4 (95% CI, 20.4–25.8) months and the prostate‐specific antigen (PSA) response rate in patients with available data was 70.9% (168/237), with no differences in mOS and PSA response rates between treatment settings. Subgroup analysis revealed higher mOS in patients without visceral metastasis versus those with such metastases (22.9 vs. 17.4 months; P = 0.022). No new safety signals were observed and the most common adverse events associated with docetaxel were granulocytopenia (5%) and leukopenia (4.5%).ConclusionData from this study showed that around three‐quarters of Chinese patients with mCRPC treated with docetaxel initiated treatment following first‐ or second‐line hormonal therapy and no new safety signals were observed.

show abstract

Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer

Cited by 3 publications

References 21 publications

A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer

A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer

A Systematic Review of the Treatment Outcomes among Prostate Cancer Patients in Africa

A multicenter observational study of the real‐world use of docetaxel for metastatic castration‐resistant prostate cancer in China

Contact Info

Product

Resources

About